Abstract. Curcumin is a polyphenolic compound which possesses anticancer potential. It has been shown to induce cell death in a variety of cancer cells, however, its effect on CAL27-cisplatin-resistant human oral cancer cells (CAR cells) has not been elucidated to date. The low water solubility of curcumin which leads to poor bioavailability, however, has been highlighted as a major limiting factor. In this study, we utilized water-soluble PLGA curcumin nanoparticles (Cur-NPs), and investigated the effects of Cur-NPs on CAR cells. The results showed Cur-NPs induced apoptosis in CAR cells but exhibited low cytotoxicity to normal human gingival fibroblasts (HGFs) and normal human oral keratinocytes (OKs). Cur-NPs triggered DNA concentration, fragmentation and subsequent apoptosis. Compared to untreated CAR cells, a more detectable amount of Calcein-AM accumulation was found inside the treated CAR cells. Cur-NPs suppressed the protein and mRNA expression levels of MDR1. Both the activity and the expression levels of caspase-3 and caspase-9 were elevated in the treated CAR cells. The Cur-NP-triggered apoptosis was blocked by specific inhibitors of pan-caspase (z-VAD-fmk), caspase-3 (z-DEVD-fmk), caspase-9 (z-LEHD-fmk) and antioxidant agent (N-acetylcysteine; NAC). Cur-NPs increased reactive oxygen species (ROS) production, upregulated the protein expression levels of cleaved caspase-3/caspase-9, cytochrome c, Apaf-1, AIF, Bax and downregulated the protein levels of Bcl-2. Our results suggest that Cur-NPs triggered the intrinsic apoptotic pathway through regulating the function of multiple drug resistance protein 1 (MDR1) and the production of reactive oxygen species (ROS) in CAR cells. Cur-NPs could be potentially efficacious in the treatment of cisplatin-resistant human oral cancer.

Introduction

Head and neck squamous cell carcinoma (HNSCC) ranks the sixth most common cancer in the world, and the survival rate has not improved significantly in the last 20 years despite the countless studies on this malignancy (1,2). In Taiwan, HNSCC has become the fourth most common cause of cancer death in males (3,4). Most of Taiwanese victims of HNSCC are diagnosed with oral squamous cell carcinoma (OSCC) due to the wide prevalence of betel-quid chewing (3,5). Depending on tumor staging, the treatment options of OSCC include surgery, radiotherapy and chemotherapy (6,7). The significant morbidities caused by cisplatin-based chemotherapy have led to continuing research on less toxic therapeutic agents (8,9). Drug resistance to cisplatin in patients with recurrent or metastatic OSCC is another challenge in oncology clinical practice (10,11).

Curcumin is a hydrophobic polyphenol derived from the plant Curcuma longa (tumeric) and has been used in Traditional Oriental Medicine for thousands of years (12-14). It is reported to possess a variety of pharmacologic effects including anti-amyloid, anti-bacterial, anti-depressant, anti-inflammatory, antioxidant and anticancer properties (12,13,15). It has also
been proven to be a modulator of intracellular signaling pathways and to target multiple molecules that inhibit cancer cell proliferation, induce apoptosis (activation of caspases or autophagy (18,19,21), to inhibit invasion (MMP-9 and cell adhesion molecules) (22-24) and to suppress inflammation molecules (such as NF-κB, TNF, IL-6, IL-1, COX-2 and 5-LOX) (25,26). The anticancer potential of curcumin has entered into phase II and phase III clinical trials for colon and pancreatic cancers (27,28).

Various animal models and human studies proved that curcumin is non-toxic even at high doses (13,29). In spite of its efficacy and safety, the low water solubility, which leads to poor bio-availability of curcumin has been considered to be a major limiting factor (30-32). The contributing reasons for reduced bio-availability of curcumin are poor absorption, high rate of metabolism and rapid systemic elimination (30-32). New drug delivery systems by oral administration are one of the means to enhance the bio-availability of curcumin. Poly(lactic-co-glycolic acid) (PLGA), a bio-degradable and bio-compatible copolymer that is approved by US Food and Drug Administration (FDA) as a therapeutic device, has been reported as a carrier of curcumin through oral administration improving bio-availability of curcumin at different levels (33-39), however, the molecular mechanism is still unclear. The factors that can affect oral bio-availability of drugs include permeability, efflux transporters (e.g., P-glycoprotein, P-gp, MDR), and enzyme induction or inhibition on intestinal epithelial cells (40,41). Studies show that the intestinal P-gp efflux pump and enterocyte-based metabolism make for a major barrier to the oral bioavailability for various compounds (40,42,43).

To improve the oral bio-availability of curcumin, we designed and developed Cur-NPs (PLGA nanoparticles loaded with curcumin) (Fig. 1A). The purpose of the research was to investigate the molecular mechanisms triggered by Cur-NPs in CAR (CAL27-cisplatin resistant) cell line which was established in our laboratory and is unique in its resistance to cisplatin treatment, and to clarify the mechanism of CUR-PLGA-NPs to enhance bioavailability.

Materials and methods

Chemicals and reagents. Cisplatin, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), poly(D,L-lactide-co-glycolide) (PLGA, copolymer ratio 75:25; molecular weight, 66,000-92,000), polyvinyl alcohol (PVA; average molecular weight, 30,000-70,000) and curcumin were purchased from Sigma-Aldrich Corp. (St. Louis, MO, USA). Fetal bovine serum (FBS), L-glutamine, penicillin G, trypsin-EDTA, 4',6-diamidino-2-phenylindole (DAPI), 2',7'-dichlorodihydrofluorescein diacetate (H$_2$DCFDA) and calcein-AM were obtained from Life Technologies (Carlsbad, CA, USA). Caspase-3 and caspase-9 activity assay kits were purchased from R&D Systems Inc. (Minneapolis, MN, USA). The primary antibodies against caspase-3, caspase-9, Endo G and Bcl-2 were obtained from Cell Signaling Technology Inc. (Beverly, MA, USA). All other antibodies used in this study and horseradish peroxidase (HRP)-conjugated secondary antibodies against rabbit or mouse immunoglobulin were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). The specific caspase inhibitors (z-VAD-fmk, z-DEVD-fmk and z-LEHD-fmk) and enhanced chemiluminescence (ECL) detection kit (Immobilon Western Chemiluminescent HRP Substrate) were obtained from Merck Millipore (Billerica, MA, USA).

Cell culture. The human head and neck carcinoma cell line CAL27 was obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). The cisplatin-resistant cell line CAR (CAL27-cisplatin resistant) was established by clonal selection of CAL27 using 10 cycles of 1 passage treatment with 10-100 µM of cisplatin followed by a recovery period of another passage (44). CAR cells were cultivated in Dulbecco’s modified Eagle’s medium (DMEM, Life Technologies) supplemented with 10% FBS, 100 µg/ml streptomycin, 100 U/ml penicillin G, 2 mM L-glutamine and 100 µM cisplatin for our study. Normal human gingival fibroblasts cells (HGF) and normal human oral keratinocyte cells (OK) were kindly provided by Dr Tzong-Ming Shih (45). Normal human gingival fibroblasts cells (HGF) and normal human oral keratinocyte cells (OK) were cultivated in DMEM (Life Technologies) supplemented with 10% FBS, 100 µg/ml streptomycin, 100 U/ml penicillin G, 2 mM L-glutamine and 80 µM cisplatin.
**Curcumin loaded nanoparticles.** Curcumin-loaded PLGA nanoparticles (Cur-NPs) were prepared by using single emulsion solvent evaporation method. In brief, curcumin (1 mg) and PLGA (10 mg) were dissolved in dichloromethane. The curcumin and PLGA solution (1 ml) was added to 2 ml of 10% (w/v) PVA surfactant solution to form an oil-in-water emulsion by sonication. The emulsion was carried out by setting sonication at 55 W of energy output for 3 min over an ice bath. The formed emulsion was dispersed drop-wise into the 0.5% (w/v) PVA solution and stirred for additional 4 h at room temperature on a magnetic stir plate to allow evaporation of organic solvent. Nanoparticles were collected by centrifugation at 12,000 rpm for 30 min and washed twice with double distilled water to remove PVA and un-encapsulated curcumin. The prepared nanoparticles were collected and lyophilized (46,47).

**Transmission electron microscopy (TEM) observation.** The morphology of test nanoparticles was examined by TEM (JEOL, Tokyo, Japan). A dilute suspension of nanoparticles (1/10 dilution) was prepared in double distilled water. One drop of this solution was placed on the TEM grid for 10 min, washed twice with double distilled water and allowed to dry overnight. The images were observed and captured at an accelerating voltage of 120 kV under a microscope (35,48,49).

**Cell viability and apoptotic morphological features.** The cell viability was assessed by the MTT assay. Briefly, CAR cells, normal human gingival fibroblasts cells (HGF) and normal human oral keratinocytes cells (OK) were cultured in a 96-well plate at the density of 1x10^4 cells per well and were incubated with 0, 10, 20, 40 and 80 µM of Cur-NPs for 24 and 48 h. After that, culture medium containing 500 µg/ml MTT was added to each well, and then incubated at 37°C for 4 h before the supernatant was removed. The formed blue formazan crystals in viable CAR cells were dissolved with isopropanol/0.04 N HCl, followed by measurement of the absorbance of each well at 570 nm with the ELISA reader keeping gene GAPDH as described elsewhere (53).

**DAPI staining for apoptosis.** CAR cells (5x10^4 cells/well) into 12-well plates were incubated without (control) or with 10, 20 and 40 µM of Cur-NPs for 24 h. Cells were washed with PBS and permeabilized in 0.1% Triton X-100 in PBS for 30 min after being fixed in 3.8% formaldehyde for 15 min. Cells were then stained with DAPI (1 µg/ml) in PBS at 37°C for 30 min, following utilizing fluorescence microscopy as described elsewhere (51).

**Internalization of curcumin.** To track the internalization of Cur-NPs, cells (1x10^5 cells/plate) were seeded on 6-well plates and incubated overnight. Subsequently, cells were treated with Cur-NPs containing 40 µM curcumin for 24 h. Finally, the cells were washed with PBS twice, and the internalized curcumin were observed under fluorescence microscopy with the filter of 488-nm excitation wavelength and 520-nm emission (30,52).

**Western blot analysis.** CAR cells (1x10^7/75-T flask) were treated with 0, 10, 20, 40 and 80 µM of Cur-NPs for 24 h or 40 µM Cur-NPs for 0, 12, 24, 36 and 48 h. Cells were then harvested, lysed and the total proteins were collected by SDS sample buffer. In brief, about 30 µg of protein from each treatment was resolved on 10% SDS-polyacrylamide gel electrophoresis (PAGE) and electro-transferred to the Immobilon-P Transfer Membrane (Merck Millipore). The transferred membranes were blocked in 5% non-fat dry milk in 20 mM Tris buffered saline/0.05% Tween-20 for 1 h at room temperature followed by incubation with appropriate primary antibodies at 4°C overnight. At the end of incubation, membranes were washed with Tris-buffered saline/Tween-20 and incubated with secondary antibodies conjugated with HRP. The blots were developed by the chemiluminescence kit and autoradiography was taken using X-ray film. Each membrane was stripped and reprobed with anti-β-actin antibody (Sigma-Aldrich Corp.) to ensure equal protein loading during the experiments (53).

**Real-time PCR analysis.** CAR cells at a density of 5x10^6 in T75 flasks were incubated with or without 40 and 80 µM of Cur-NPs for 24 h. Cells were collected, and total RNA was extracted by the Qiagen RNeasy mini kit (Qiagen Inc., Valencia, CA, USA). Each RNA sample was individually reverse-transcribed using the High Capacity cDNA Reverse Transcription kits according to the standard protocols (Applied Biosystems, Foster City, CA, USA) (54). Quantitative PCR was assessed for amplifications with 2X SYBR-Green PCR Master mix (Applied Biosystems) and forward (GTGT GGTGAGTCCGAAACCTGTAT) and reverse (TCTCAAT CTCATCAGTGTTAGA) primers for MDR1 gene (diallyl sulfide, diallyl disulfide and diallyl trisulfide affect drug resistant gene expression in colo 205 human colon cancer cells in vitro and in vivo). The 7300 Real-Time PCR (Applied Biosystems) was run in triplicate, and each value was expressed as the comparative threshold cycle (CT) method for the house-keeping gene GAPDH as described elsewhere (55).

**Calcine-AM assay.** CAR cells (2x10^5 cells/well) into 12-well plates were treated with or without 0, 10, 20, 40 and 80 µM of Cur-NPs. After a 24-h exposure, cells were washed twice, and 200 nM calcine-AM was added to each incubation medium for 30 min. The specific calcine fluorescence intensity was measured by flow cytometry, and at least ten thousand events were analyzed per sample as previously described (55).

**Assays for caspase-3 and caspase-9 activities.** CAR cells (approximately 1x10^7/75-T flask) were exposed to 0, 10, 20, 40 and 80 µM of Cur-NPs for 24 h. Subsequently, cells were harvested, and cell lysates were assessed in accordance with the manufacturer's instruction provided in the caspase-3 and caspase-9 Colorimetric Assay kits (R&D Systems Inc.). Cell lysate containing 50 µg protein was then incubated for 1 h at 37°C with specific caspase-3 substrate (DEVD-pNA) or caspase-9 substrate (LEHD-pNA) and the reaction buffer (provided in the kits) and determined by measuring OD at 405 of the released pNA as previously described (56).

**Detection of ROS generation.** CAR cells (2x10^5 cells/well) were treated with 25 µM of Cur-NPs for 0, 3, 6, 12 and 24 h,
harvested, and incubated with 10 µM H$_2$DCFDA at 37°C for 30 min. DCF fluorescence oxidized by ROS was detected by flow cytometry as described elsewhere (57).

**Effects of the caspase inhibitors and ROS scavenger on cell viability.** CAR cells at a density of 2x10$^5$ cells/well into 12-well plates were preincubated with 10 µM z-VAD (a pan-caspase inhibitor), 10 µM z-DEVE (a caspase-3 inhibitor), 10 µM z-LEHD (a caspase-9 inhibitor) and N-acetyl-L-cysteine (NAC), a ROS scavenger for 2 h followed by treatment with or without 25 µM Cur-NPs. Cells were thereafter harvested at 24 h to investigate the percentage of viable cells as elsewhere described (57).

**Statistical analysis.** All the statistical results are performed as the mean ± standard error of the mean (SEM) for the indicated number of independent experiments. Statistical analyses of data were done using one-way ANOVA followed by Student's t-test, and the levels of p<0.001 was considered significant between the treated and untreated groups (58).

**Results**

Cur-NPs reduce the viability of human oral cancer CAL27-cisplatin resistant (CAR) cells, but not the cytotoxic effect on normal cells. CAR cells were exposed to Cur-NPs (0, 10, 20, 40 and 80 µM) for 24 and 48 h, and
cells from each treatment were collected then determined using MTT assay. Results demonstrated that even though 10 µM of Cur-NPs showed no effect on viability and the concentrations of Cur-NPs treatment (20, 40 and 80 µM) significantly decreased cell viability in CAR cells in a concentration- and time-dependent manner (bottom panels of Fig. 2A and B). The cells after Cur-NPs challenge were investigated for morphological changes such as shrinkage and rounding (an apoptotic characteristic) as can be seen in the top of Fig. 2A and B. Importantly, Cur-NPs have less toxicity (no viability impact and morphological traits) in normal cell lines, including normal human gingival fibroblasts (HGF) and normal human oral keratinocyte cells (OK) (IC$_{50}$ >80 µM) (Fig. 2C and D). These results suggest that Cur-NPs exhibit anticancer action against cisplatin-resistant oral tumor cells in vitro.

Cur-NPs induce apoptosis and suppresses multiple drug resistance protein 1 (MDR1) in CAR cells. After treatment with various concentrations (10, 20 and 40 µM) of Cur-NPs for 24 h, the ability of induction of nuclear condensation was employed by DAPI staining. The results shown in Fig. 3A revealed apoptotic evidence visualized in Cur-NPs-treated CAR cells and this effect is concentration-dependent. The nanoparticle form of curcumin improves the drawback of curcumin solubility in water and increases the amount of curcumin delivered into cells. Cellular uptake of Cur-NPs was observed by visualizing the green fluorescence of curcumin using fluorescence microscopy (Fig. 3B). Intensified fluorescence was observed in the cytoplasm and nucleus of cells treated with Cur-NPs, indicating the amount of curcumin internalized to the cells. Strikingly, our data indicate attenuation of the expression of MDR1 in Cur-NP-treated CAR cells.
We also found that Cur-NPs at 40 and 80 µM inhibited the level of MDR1 gene expression in CAR cells (Fig. 3C and D). Alternatively, the drug-resistance expression in CAR cells after exposure to Cur-NPs was detected by calcein-AM staining and flow cytometry. Fig. 3E shows Cur-NPs decreased drug interaction with multidrug resistance protein in CAR cells. Altogether, these results demonstrate that induction of CAR cell apoptosis occurred, as well as suppression of multiple drug resistance by Cur-NPs.

Cur-NPs trigger intrinsic apoptotic cell death in CAR cells. To address whether Cur-NPs induce apoptosis in CAR cells, cells were treated with Cur-NPs (0, 10, 20, 40 and 80 µM) for 24 h before subjected to caspase-3/-9 activity. Our data as shown in Fig. 4A and B present that Cur-NPs stimulated caspase-3 (Fig. 4A) and caspase-9 (Fig. 4B) activity at a 24-h exposure. In order to confirm the roles of caspase cascade-mediated apoptosis by Cur-NPs, we treated CAR cells without or with z-VAD (a pan-caspase inhibitor), z-DEVE (a caspase-3 inhibitor) and z-LEHD (a caspase-9 inhibitor) before exposure to Cur-NPs to investigate viability. Our data showed that z-VAD significantly suppressed Cur-NPs-reduced viability by up to 90% in CAR cells (Fig. 4C). Moreover, both caspase protease inhibitors (z-DEVE and z-LEHD) substantially protected against Cur-NP-triggered cell death and viability of CAR cells (Fig. 4D). Based on these findings, we provide evidence that the intrinsic caspase contributed to Cur-NP-induced apoptosis in CAR cells.

Cur-NP enhance ROS generation and promote mitochondria-dependent CAR cell apoptosis. We further clarified if oxidative stress regulates Cur-NP-provoked cell death, and our findings demonstrated that Cur-NPs increased ROS levels in CAR cells as shown in Fig. 5A. Results showed that the presence of NAC dramatically protected CAR cells from cell death (Fig. 5B). We further examined the effects of Cur-NPs on mitochondria-dependent signaling in CAR cells. The immunoblot analysis showed that the protein levels of cleaved caspase-3, cleaved caspase-9, cytochrome c, Apaf-1, AIF and Endo G were increased in Cur-NP-treated CAR cells (Fig. 5C). As shown in Fig. 5D, Cur-NP treatment resulted in upregulation of Bax but downregulation of Bcl-2 protein level in treated cells. Thus, we summarize the current understanding in CAR cells that after Cur-NP treatment, cell death is caused through mitochondrial caspase cascade-dependent signals in vitro.

Discussion

Since poor bioavailability is a major drawback of curcumin, various formulation techniques have been utilized to circumvent this pitfall (30,59,60). Use of nanoparticles is one of the
means that have been investigated for this purpose. Anand et al. pointed out that nanoparticle-based delivery systems are probably suitable for hydrophobic agents to enhance the solubility of poorly aqueous-soluble agents like curcumin (61). In a study reported by Yallapu et al., the curcumin-loaded cellulose nanoparticles showed improved anticancer efficacy compared to free curcumin (23,52,62). Anand et al. reported that curcumin-loaded PLGA nanoparticle formulation is at least as potent as, or more potent, than curcumin in inducing cancer cell apoptosis, and has enhanced cellular uptake, increased bioactivity in vitro and superior bioavailability in vivo over curcumin (48). The above-mentioned studies all indicate that Cur-NPs possess significantly greater water solubility and systemic bioavailability than free curcumin (23,27,46-48). It motivated us to design and prepare our own water-soluble curcumin nanoparticles (Cur-NPs) (Fig. 1A) which indeed exhibited anticancer properties in CAL27-cisplatin resistant human CAR oral cancer cells. CUR-NPs were incorporated into PLGA nanoparticles (93.7%) through a modified single emulsion technique. The morphology of the obtained particles was examined under TEM. Fig. 1B showed that the produced Cur-NPs are spherical in shape with a smooth surface. The size of Cur-NPs was on average 180 nm in diameter (data not shown) which meets the criteria for ‘nanoparticles’.

A recent study by Yin et al. demonstrated that their Cur-NPs are effective in inhibiting the growth of human lung cancer with little toxicity to normal tissues in an established A549 transplanted mouse model (63). As shown in Fig. 2A and B, the Cur-NPs used in our study also caused anti-proliferation effects on CAR cells in a dose- and time-dependent manner but little cytotoxicity to the normal human gingival fibroblasts cells (HGF) and normal human oral keratinocyte cells (OK) (Fig. 2C and D). The results suggested that Cur-NPs could represent promising candidates as a safe anti-oral cancer drug.

Overexpression of MDR1 is one of the main reasons for multidrug resistance to chemotherapeutic agents. Misra et al. combined doxorubicin and curcumin in PLGA-nanoparticles and found this approach enhanced the cytotoxicity by promoting the apoptotic response in multidrug-resistant K562 leukemia cells (64). Doxorubicin-curcumin composite nanoparticle formulation inhibited the MDR and caused striking growth inhibition both in vitro and in vivo in several models of DOX-resistant myeloma, acute leukemia, prostate cancer and ovarian cancer cells (65). In our preliminary
studies, real-time PCR array analysis revealed higher level of MDR1 expression (ABCB1) in untreated CAR cells than in untreated CAL27 oral cancer cells (data not shown). The results in the present research showed that the mRNA and protein level of MDR1 were both decreased in CAR cells (Fig. 3C and D) after treatment with Cur-NPs. The retention rate of Calcein-AM within Cur-NPs-treated CAR cells (Fig. 3E) indicated that Cur-NPs could reduce the interaction between drugs and multidrug resistance protein in a dose-dependent manner. The data suggested that Cur-NPs induce CAR cell apoptosis via suppressing the expression of multidrug resistance protein due to more retention of the therapeutic medicine within the cells. Some other studies also reported that curcumin downregulates P-glycoprotein (P-gp) expression in drug-resistant SKOV3 human ovarian adenocarcinoma cells through inhibiting NF-κB activity (66,67). Punfa et al demonstrated that targeting P-gp on the cell surface membrane of KB-V1 cancer cells (higher expression of P-gp) with Cur-NPs-APgp enhanced the cellular uptake and cytotoxicity of curcumin (68). These results suggested MDR1 or P-gp on the cell surface membrane is the major target of Cur-NPs.

This is the first study investigating the anti-head and neck squamous cell carcinoma effects of Cur-NPs on human CAL27-cisplatin resistant human oral cancer cells (CAR cells). Our results showed that Cur-NPs inhibited CAR cell growth and induced apoptotic cell death in a concentration and time-dependent manner. Fig. 4A and B showed Cur-NPs provoked cell apoptosis through the activation of caspase-9 and caspase-3, whereas a pretreatment of pan-caspase, caspase-9 and caspase-3 inhibitors led to increased viable CAR cells compared to the un-pretreated group (Fig. 4C and D). The results suggested that Cur-NPs-induced apoptosis in CAR cells might be carried out through the intrinsic signaling pathway, or mitochondrial-dependent pathway, which has connection with the activation of caspase-9 and caspase-3.

Various studies reported that curcumin induces apoptosis through intrinsic signaling pathways by depolarizing the mitochondrial membrane and triggering the release of cytochrome c (69-71). Dilnawaz et al utilized curcumin-loaded magnetic nanoparticle (Cur-MNP and Tf-Cur-MNP) formulations to address K562 cells and induced a rapid decrease in mitochondrial membrane potential with release of cytochrome c into cytosol, followed by cleavage of caspase-9 and caspase-3 (72). The result in Fig. 5A shows Cur-NPs provoked intrinsic apoptotic signaling in CAR cells through the production of reactive oxygen species (ROS). More viable CAR cells were preserved when being pretreated with antioxidant agent (N-acetylcysteine; NAC) compared to the un-pretreated group (Fig. 5B). Results of western blot analysis indicated that Cur-NPs elevated the protein level of active form of caspase-3 and caspase-9 (Fig. 5C), as well as that of cytochrome c, Apaf-1, AIF (Fig. 5C) and pro-apoptotic protein Bax (Fig. 5D) while Bcl-2 expression was suppressed (Fig. 5D). Our results suggested that Cur-NP-induced apoptosis could be carried out through the reactive oxygen species (ROS) production.

In summary, Cur-NPs induce cell apoptosis in CAL27-cisplatin resistance human oral cancer cells (CAR cells) and inhibit cell growth but possess little cytotoxicity to normal human gingival fibroblasts cells (HGF) and normal human oral keratinocyte cells (OK). The findings suggest that Cur-NPs trigger apoptotic cell death through regulating the function of MDR1 and the production of reactive oxygen species (ROS), and the activation of caspase-9 and caspase-3 connected to intrinsic signaling pathway is the major pharmacologic action of Cur-NPs. Cur-NPs show promise for development as a novel medicine against cisplatin resistant human oral cancer.

Acknowledgements

This study was supported in part by a research grant from the China Medical University (CMU101-N2-07) to S.-F.P.; and in part by a grant from the National Science Council of Taiwan to T.-S.W. and (102-2320-B-039-028-MY3) awarded to J.-S. Yang.
References


